Improved access to psoriatic arthritis treatments17th June 2010
The National Institute for Health and Clinical Excellence (NICE) has published new guidelines to help improve access to treatments for psoriatic arthritis.
NICE has published final draft guidance on the use of etanercept (brand name Enbrel), infliximab (brand name Remicade) and adalimumab (brand name Humira), which are recommended for adults with active and progressive psoriatic arthritis, as long as certain criteria are met. In its latest guidance, NICE proposes wider access to infliximab than had originally been recommended in its draft guidance, now recommending it as an option alongside etanercept and adalimumab.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: Improved access to psoriatic arthritis treatments
Author: Mark Nicholls
Article Id: 15172
Date Added: 17th Jun 2010